The Dako PD-L1 IHC 22C3 PharmDx Assay has been approved as a companion diagnostic to identify patients with with locally advanced or metastatic urothelial carcinoma who are cisplatin-ineligible for ...
Hossein Borghaei, DO, MS: As far as PD-L1 testing, I’m pretty sure I know how it is at your center because we have very similar systems. But that’s much simpler testing. That’s immunohistochemistry ...
Programmed Death-Ligand 1 (PD-L1) biomarker testing is a diagnostic procedure used in the field of oncology to assess the expression of PD-L1 proteins in tumor cells. PD-L1 is a protein that can be ...
Guideline updates discussed Thursday at the 2019 National Comprehensive Cancer Network Annual Conference reflect recent practice-changing clinical trials involving pembrolizumab and chemotherapy. The ...
The global PD-L1 biomarker testing market is on a strong growth trajectory, rising from USD 777.2 million in 2025 to USD 1,690.8 million by 2035, at a CAGR of 8.1% during the forecast period. PD-L1 ...
-- PD-L1 is a protein involved in the suppression of the immune system, which can impact the body's ability to fight cancer -- The VENTANA PD-L1 (SP142) Assay(1) to determine PD-L1 expression in ...
Two viewpoint articles published in JAMA Oncology provide opposing opinions on the benefit of testing for programmed death-ligand 1 (PD-L1) expression in patients with non-small-cell lung cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback